Crossmark

Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT2C, 5-HT2B, and 5-HT7 Receptor Binding at Therapeutically Relevant Concentrations

Crossref DOI link: https://doi.org/10.1007/s40268-026-00543-y

Published Online: 2026-04-03

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Garcia-Olivares, Jennie https://orcid.org/0000-0002-6164-0744
Yegla, Brittney

Koch, Jennifer

Yu, Chungping

Rubin, Jonathan
Funding

Funding for this research was provided by:

Supernus Pharmaceuticals
License Information

Text and Data Mining valid from 2026-03-01

Version of Record valid from 2026-04-03
More Information

Article History

Received: 29 October 2025

Accepted: 16 March 2026

First Online: 3 April 2026

Declarations

:

: Medical writing support, funded by Supernus, was provided by Callie A. S. Corsa, PhD, ISMPP CMPP TM , and Lisa M. Pitchford, PhD, ISMPP CMPP TM , of JB Ashtin.

: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

: Animal experimentation for this study was conducted in accordance with the UK Animals (Scientific Procedures) Act 1986 and the transposed EU directive 2010/63/EU. All procedures were approved by the Animal Ethical Review Committee of Imperial College.

: JG-O, BY, JK, CY, and JR are employees of Supernus Pharmaceuticals, Inc.

: JG-O, BY, CY, and JR contributed to the study concept and design. JG-O contributed to statistical analysis. JG-O, BY, JK, CY, and JR contributed to data interpretation. All authors have read and approved the final version.

: Not applicable.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below